Claude Martin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Claude Martin has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Marc Leone
Affiliation Aix-Marseille Université, APHM, Hôpital Nord, Service d’Anesthésie et de Réanimation, Marseille, France
9 shared publications Andrea Kurz
Professor, The Cleveland Clinic, Department of Outcomes Research, Cleveland, Ohio
3 shared publications- Claire Bonithon-Kopp
University Hospital of Dijon, Clinical Investigation Centre
3 shared publications - Claude Jacquot
Pôle Anesthésie Réanimation, CHU de Grenoble, La Tronche, France
3 shared publications Eric Vicaut
Professor, Hôpital Fernand Widal, Service Biophysique et Traitement de l’Image, Laboratoire de Biophysique, Paris, France
3 shared publicationsHugo Van Aken
Professor, Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany
3 shared publications
Latest Publications
- 1 June 2019
- Published by Wolters Kluwer Health in European Journal of Anaesthesiology
- Vol. 36 (6) , 387-389
The anaesthesiologist
- 1 June 2019
- Published by Wolters Kluwer Health in European Journal of Anaesthesiology
- Vol. 36 (6) , 387-389
The anaesthesiologist
- 1 January 2019
- Published by Springer Nature
- p. 411-418
Cardiopulmonary Monitoring of Septic Shock
- 3 June 2015
- Published by Springer Nature in Intensive Care Medicine
- Vol. 41 (7) , 1378
Acute mesenteric ischemia, procalcitonin, and intensive care unit
- 3 June 2015
- Published by Springer Nature in Intensive Care Medicine
- Vol. 41 (7) , 1378
Acute mesenteric ischemia, procalcitonin, and intensive care unit
- Open Access
- 10 March 2015
- Published by Springer Nature in Critical Care
- Vol. 19 (1) , 1-7
Optimizing mean arterial pressure in septic shock: a critical reappraisal of the literature
Guidelines recommend that a mean arterial pressure (MAP) value greater than 65 mm Hg should be the initial blood pressure target in septic shock, but what evidence is there to support this statement? We searched Pubmed and Google Scholar by using the key words ‘arterial pressure’, ‘septic shock’, and ‘norepinephrine’ and retrieved human studies published between 1 January 2000 and 31 July 2014. We identified seven comparative studies: two randomized clinical trials and five observational studies. The results of the literature review suggest that a MAP target of 65 mm Hg is usually sufficient in patients with septic shock. However, a MAP of around 75 to 85 mm Hg may reduce the development of acute kidney injury in patients with chronic arterial hypertension. Because of the high prevalence of chronic arterial hypertension in patients who develop septic shock, this finding is of considerable importance. Future studies should assess interactions between time, fluid volumes administered, and doses of vasopressors.
- 10 March 2015
- Published by Springer Nature in Critical Care
- Vol. 19 (1) , 1-7
Open AccessOptimizing mean arterial pressure in septic shock: a critical reappraisal of the literature
Guidelines recommend that a mean arterial pressure (MAP) value greater than 65 mm Hg should be the initial blood pressure target in septic shock, but what evidence is there to support this statement? We searched Pubmed and Google Scholar by using the key words ‘arterial pressure’, ‘septic shock’, and ‘norepinephrine’ and retrieved human studies published between 1 January 2000 and 31 July 2014. We identified seven comparative studies: two randomized clinical trials and five observational studies. The results of the literature review suggest that a MAP target of 65 mm Hg is usually sufficient in patients with septic shock. However, a MAP of around 75 to 85 mm Hg may reduce the development of acute kidney injury in patients with chronic arterial hypertension. Because of the high prevalence of chronic arterial hypertension in patients who develop septic shock, this finding is of considerable importance. Future studies should assess interactions between time, fluid volumes administered, and doses of vasopressors.
- 1 February 2015
- Published by Elsevier in Anaesthesia Critical Care & Pain Medicine
- Vol. 34 (1) , 41-44
Implementation of lung ultrasound in polyvalent intensive care unit: Impact on irradiation and medical cost
- 1 February 2015
- Published by Elsevier in Anaesthesia Critical Care & Pain Medicine
- Vol. 34 (1) , 41-44
Implementation of lung ultrasound in polyvalent intensive care unit: Impact on irradiation and medical cost
- 1 November 2013
- Published by Elsevier in Annales Françaises d'Anesthésie et de Réanimation
- Vol. 32 (11) , 729-731
Réanimations : travailler (beaucoup) plus pour gagner plus, mais toujours pas assez
- 1 November 2013
- Published by Elsevier in Annales Françaises d'Anesthésie et de Réanimation
- Vol. 32 (11) , 729-731
Réanimations : travailler (beaucoup) plus pour gagner plus, mais toujours pas assez
- 1 October 2013
- Published by Wolters Kluwer Health in Survey of Anesthesiology
- Vol. 57 (5) , 246-247
Effect of Waxy Maize-Derived Hydroxyethyl Starch 130/0.4 on Renal Function in Surgical Patients
- 1 October 2013
- Published by Wolters Kluwer Health in Survey of Anesthesiology
- Vol. 57 (5) , 246-247
Effect of Waxy Maize-Derived Hydroxyethyl Starch 130/0.4 on Renal Function in Surgical Patients
- Open Access
- 1 September 2013
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 119 (3) , 736-737
In Reply
We thank Drs. Groeneveld et al. and Widermann for their interesting comments on our article.1 Groeneveld et al. made a remark that in CHEST trial, the temporal effects of serum creatinine increase became apparent only between days 1 and 4. Yet the increase was from ±110 to ±116 µm, which is certainly not clinically relevant. Serum creatinine or creatinine clearance are not perfect biomarkers for renal injury, but no other marker is universally accepted in the field even though many have been studied. Although the CHEST trial2 might be a landmark study, it was conducted in patients in intensive care unit, and we purposely excluded this patient population from our meta-analysis. In the CHEST trial2 only 1,574 of 6,742 patients were randomized after elective surgery (the type of patients we evaluated). When such patients were admitted to intensive care units, it was probably because they suffered intraoperative complications, which may have put them at higher risk of delayed renal complications.We do not think that the comparison of our work with the meta-analysis by Zarychanski et al.3 is adequate. This meta-analysis has included very heterogeneous groups of patients, including severely ill patients in intensive care units, many of them with different forms of shock including septic shock. Such a population is at high risk of organ dysfunction, including acute kidney failure, and cannot be compared with elective surgical patients. Also, we do not think that our meta-analysis is comparable with analysis by Gattas et al.4 In this meta-analysis, the studies showing a higher risk for the need of renal replacement therapy (fig 3, top panel4) were all conducted in patients in intensive care unit, with only one exception (Nagpal et al.). In the middle panel of figure 3 of our article,1 trials conducted in surgical patients are presented. These trials were not associated with a higher risk of renal replacement therapy (risk ratio, 0.46; 95% CI, 0.10–2.05; P = 0.794). Therefore both meta-analyses either are inadequate to address the clinical question that we wanted to address or found comparable evidence.Surgical patients were also evaluated by Van Der Linden et al.5. In their meta-analysis, 2,139 patients treated with tetrastarches were compared with 2,390 patients treated with a comparator. From 39 trials, the authors concluded that tetrastarches used during surgery did not induce adverse renal effects as assessed by changes in serum creatinine or need for renal replacement therapy. The authors reported 21 studies documenting serum creatinine or creatinine clearance after administration of 130/0.4 starch or other tested fluids. One thousand five patients were given a tetrastarch and 1,051 patients were given a comparator. The period for which creatinine was reported covered up to 14 days after administration. All but three studies showed no difference in peak creatinine concentration. Two studies found a statistically better outcome for the tetrastarch. The authors concluded that they could not detect a hint for an adverse signal after the use of modern starch in surgical patients.5 The risk of excessive bleeding was out of the scope of our meta-analysis, but the results of the Van Der Linden meta-analysis are reassuring with this regard. Every meta-analysis can only be as reliable as the data available. In this way, it is in fact limited, and this point was emphasized at the end of our discussion. But, even though only two of the trials in the meta-analysis were primarily designed to evaluate the renal effect of hydroxyethyl starch 130/0.4, this side effect of colloids was well known since long and thus was an integral safety parameter in all of these trials.We are confident that our conclusions are meaningful today and can hold in the light of upcoming evidence. Although Groeneveld et al. point out that a retrospective analysis has found an association between hydroxyethyl starch 130/0.4 and renal replacement therapy, we would like to draw the readers’ attention to a recently published prospective randomized study in patients undergoing abdominal surgery by Feldheiser et al.6 demonstrating that a stringent treatment algorithm and an adequate monitoring results in better hemodynamic stability and reduced need for fresh-frozen plasma. This study included a 3-month follow-up and measured the sensitive renal marker neutrophil gelatinase-associated lipocalin. If older studies might not provide the evidence, we would wish for today, this is also true for all studies that did not use rigorous protocols to identify patients who were in need of volume therapy.
- 1 September 2013
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 119 (3) , 736-737
Open AccessIn Reply
We thank Drs. Groeneveld et al. and Widermann for their interesting comments on our article.1 Groeneveld et al. made a remark that in CHEST trial, the temporal effects of serum creatinine increase became apparent only between days 1 and 4. Yet the increase was from ±110 to ±116 µm, which is certainly not clinically relevant. Serum creatinine or creatinine clearance are not perfect biomarkers for renal injury, but no other marker is universally accepted in the field even though many have been studied. Although the CHEST trial2 might be a landmark study, it was conducted in patients in intensive care unit, and we purposely excluded this patient population from our meta-analysis. In the CHEST trial2 only 1,574 of 6,742 patients were randomized after elective surgery (the type of patients we evaluated). When such patients were admitted to intensive care units, it was probably because they suffered intraoperative complications, which may have put them at higher risk of delayed renal complications.We do not think that the comparison of our work with the meta-analysis by Zarychanski et al.3 is adequate. This meta-analysis has included very heterogeneous groups of patients, including severely ill patients in intensive care units, many of them with different forms of shock including septic shock. Such a population is at high risk of organ dysfunction, including acute kidney failure, and cannot be compared with elective surgical patients. Also, we do not think that our meta-analysis is comparable with analysis by Gattas et al.4 In this meta-analysis, the studies showing a higher risk for the need of renal replacement therapy (fig 3, top panel4) were all conducted in patients in intensive care unit, with only one exception (Nagpal et al.). In the middle panel of figure 3 of our article,1 trials conducted in surgical patients are presented. These trials were not associated with a higher risk of renal replacement therapy (risk ratio, 0.46; 95% CI, 0.10–2.05; P = 0.794). Therefore both meta-analyses either are inadequate to address the clinical question that we wanted to address or found comparable evidence.Surgical patients were also evaluated by Van Der Linden et al.5. In their meta-analysis, 2,139 patients treated with tetrastarches were compared with 2,390 patients treated with a comparator. From 39 trials, the authors concluded that tetrastarches used during surgery did not induce adverse renal effects as assessed by changes in serum creatinine or need for renal replacement therapy. The authors reported 21 studies documenting serum creatinine or creatinine clearance after administration of 130/0.4 starch or other tested fluids. One thousand five patients were given a tetrastarch and 1,051 patients were given a comparator. The period for which creatinine was reported covered up to 14 days after administration. All but three studies showed no difference in peak creatinine concentration. Two studies found a statistically better outcome for the tetrastarch. The authors concluded that they could not detect a hint for an adverse signal after the use of modern starch in surgical patients.5 The risk of excessive bleeding was out of the scope of our meta-analysis, but the results of the Van Der Linden meta-analysis are reassuring with this regard. Every meta-analysis can only be as reliable as the data available. In this way, it is in fact limited, and this point was emphasized at the end of our discussion. But, even though only two of the trials in the meta-analysis were primarily designed to evaluate the renal effect of hydroxyethyl starch 130/0.4, this side effect of colloids was well known since long and thus was an integral safety parameter in all of these trials.We are confident that our conclusions are meaningful today and can hold in the light of upcoming evidence. Although Groeneveld et al. point out that a retrospective analysis has found an association between hydroxyethyl starch 130/0.4 and renal replacement therapy, we would like to draw the readers’ attention to a recently published prospective randomized study in patients undergoing abdominal surgery by Feldheiser et al.6 demonstrating that a stringent treatment algorithm and an adequate monitoring results in better hemodynamic stability and reduced need for fresh-frozen plasma. This study included a 3-month follow-up and measured the sensitive renal marker neutrophil gelatinase-associated lipocalin. If older studies might not provide the evidence, we would wish for today, this is also true for all studies that did not use rigorous protocols to identify patients who were in need of volume therapy.
- Open Access
- 6 August 2013
- Published by Springer Nature in Critical Care
- Vol. 17 (4) , 1-6
Routine use of Staphylococcus aureus rapid diagnostic test in patients with suspected ventilator-associated pneumonia
Introduction: In patients with ventilator-associated pneumonia (VAP), administration of an appropriate empirical antimicrobial treatment is associated with improved outcomes, leading to the prescription of broad-spectrum antibiotics, including a drug active against methicillin resistant Staphylococcus aureus (MRSA). In order to avoid the overuse of antibiotics, the present study aimed to evaluate the technical characteristics of a rapid diagnostic test (Cepheid Xpert assay) in patients with suspected VAP. Methods: From June 2011 to June 2012, in patients with suspected VAP, a sample from the bronchialalveolar lavage (BAL) or miniBAL was tested in a point-of-care laboratory for a rapid diagnostic test of methicillin susceptible Staphylococcus aureus (MSSA) and MRSA. Then, the result was compared to the quantitative culture with a threshold at 104 colony-forming units per milliliter for bronchoalveolar lavage and 103 colony-forming units per milliliter for minibronchoalveolar lavage. The study was performed in three intensive care units at two institutions. Results: Four hundred, twenty-two samples from 328 patients were analyzed. The culture of 6 (1.1%) and 28 (6.5%) samples were positive for MRSA and MSSA. The test was not interpretable in 41 (9.3%) patients. The negative predictive values of the rapid detection test were 99.7% (98.1 to 99.9%) and 99.8% (98.7 to 99.9%) for MSSA and MRSA, respectively. Conclusion: The rapid diagnostic test is reliable in excluding the presence of MSSA and MRSA in the samples of patients with suspected VAP. Its utility should be regarded depending on the prevalence of MRSA.
- 6 August 2013
- Published by Springer Nature in Critical Care
- Vol. 17 (4) , 1-6
Open AccessRoutine use of Staphylococcus aureus rapid diagnostic test in patients with suspected ventilator-associated pneumonia
Introduction: In patients with ventilator-associated pneumonia (VAP), administration of an appropriate empirical antimicrobial treatment is associated with improved outcomes, leading to the prescription of broad-spectrum antibiotics, including a drug active against methicillin resistant Staphylococcus aureus (MRSA). In order to avoid the overuse of antibiotics, the present study aimed to evaluate the technical characteristics of a rapid diagnostic test (Cepheid Xpert assay) in patients with suspected VAP. Methods: From June 2011 to June 2012, in patients with suspected VAP, a sample from the bronchialalveolar lavage (BAL) or miniBAL was tested in a point-of-care laboratory for a rapid diagnostic test of methicillin susceptible Staphylococcus aureus (MSSA) and MRSA. Then, the result was compared to the quantitative culture with a threshold at 104 colony-forming units per milliliter for bronchoalveolar lavage and 103 colony-forming units per milliliter for minibronchoalveolar lavage. The study was performed in three intensive care units at two institutions. Results: Four hundred, twenty-two samples from 328 patients were analyzed. The culture of 6 (1.1%) and 28 (6.5%) samples were positive for MRSA and MSSA. The test was not interpretable in 41 (9.3%) patients. The negative predictive values of the rapid detection test were 99.7% (98.1 to 99.9%) and 99.8% (98.7 to 99.9%) for MSSA and MRSA, respectively. Conclusion: The rapid diagnostic test is reliable in excluding the presence of MSSA and MRSA in the samples of patients with suspected VAP. Its utility should be regarded depending on the prevalence of MRSA.
- 1 February 2013
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 118 (2) , 387-394
Effect of Waxy Maize-derived Hydroxyethyl Starch 130/0.4 on Renal Function in Surgical Patients
Background: The aim of this meta-analysis was to evaluate renal safety with the active substance of the latest generation of waxy maize-derived hydroxyethyl starch in surgical patients. The authors focused on prospective, randomized, controlled studies that documented clinically relevant variables with regard to renal effects of waxy maize-derived hydroxyethyl starch 130/0.40. Materials and methods: The authors carefully searched for all available prospective, randomized studies and evaluated the greatest delta from baseline values in renal safety variables (serum creatinine values, calculated creatinine clearance, incidence of renal replacement therapy, and acute renal failure). The authors included 17 studies that analyzed patients (n = 1,230) undergoing a variety of surgical procedures. Results: For maximum serum creatinine values, the effect size estimate was 0.068 (95% CI = −0.227 to 0.362), P = 0.65. For calculated creatinine clearance values, pooled risk difference was 0.302 (95% CI = −0.098 to 0.703), P = 0.14. For incidence of acute renal failure, pooled risk difference was 0.0003 (95% CI = −0.018 to 0.019), P = 0.98. For incidence of renal replacement therapy, pooled risk difference was −0.003 (95% CI = −0.028 to 0.022), P = 0.85. Conclusions: The authors found no evidence for renal dysfunction caused by modern waxy maize-derived hydroxyethyl starch 130/0.40 in surgical patients.
- 1 February 2013
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 118 (2) , 387-394
Effect of Waxy Maize-derived Hydroxyethyl Starch 130/0.4 on Renal Function in Surgical Patients
Background: The aim of this meta-analysis was to evaluate renal safety with the active substance of the latest generation of waxy maize-derived hydroxyethyl starch in surgical patients. The authors focused on prospective, randomized, controlled studies that documented clinically relevant variables with regard to renal effects of waxy maize-derived hydroxyethyl starch 130/0.40. Materials and methods: The authors carefully searched for all available prospective, randomized studies and evaluated the greatest delta from baseline values in renal safety variables (serum creatinine values, calculated creatinine clearance, incidence of renal replacement therapy, and acute renal failure). The authors included 17 studies that analyzed patients (n = 1,230) undergoing a variety of surgical procedures. Results: For maximum serum creatinine values, the effect size estimate was 0.068 (95% CI = −0.227 to 0.362), P = 0.65. For calculated creatinine clearance values, pooled risk difference was 0.302 (95% CI = −0.098 to 0.703), P = 0.14. For incidence of acute renal failure, pooled risk difference was 0.0003 (95% CI = −0.018 to 0.019), P = 0.98. For incidence of renal replacement therapy, pooled risk difference was −0.003 (95% CI = −0.028 to 0.022), P = 0.85. Conclusions: The authors found no evidence for renal dysfunction caused by modern waxy maize-derived hydroxyethyl starch 130/0.40 in surgical patients.